SPARC, also referred to as osteonectin, induced apoptosis in ovarian cancer cells [180], mitigated proliferation of prostate cancer cells [181], inhibited proliferation and promoted apoptosis of implanted lung carcinoma and T-lymphoma cells in vivo in mice [182], and reduced tumor growth but accelerated invasion in the brain in a murine glioma model [183]. Here, SPARC is linked to lung carcinoma.